

14. A method of making a cardiovascular protective dosage unit comprising
formulating a single dosage unit consisting essentially of a beta-adrenergic
blocking agent and a platelet inhibitor in a quantity sufficient to provide a
cardiovascular protective dosage.
16. A medicament dosage unit consisting essentially of a beta-adrenergic blocker and
aspirin combined in a single dosage unit in sufficient quantity to provide a
cardiovascular protective dosage.

REMARKS

Applicant thanks the Office for the attention accorded the present Application in the August 13, 2002, Office Action. In that Action, Claims 1-7, 9-11 and 13-17 were rejected under 35 USC §102(a) as being anticipated by Powell et al.

Applicants have amended Claims 1, 9, 14, and 16 to limit the combination, single dosage unit to only effective ingredients in an amount sufficient to provide a cardiovascular protective dosage. Support for such amendments can be found in Applicants' disclosure on Page 4, lines 9-18.

35 USC §102(b) rejections:

The Office has rejected Claims 1-7, 9-11 and 13-17 under 35 USC §102(a) as anticipated by Powell et al. The Office states that "Powell et al. teach vasoepitidase